Perceptive Advisors LLC Purchases 205,650 Shares of Viewray Inc (VRAY)

Share on StockTwits

Perceptive Advisors LLC boosted its position in Viewray Inc (NASDAQ:VRAY) by 5.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,905,650 shares of the company’s stock after purchasing an additional 205,650 shares during the quarter. Perceptive Advisors LLC owned about 4.08% of Viewray worth $21,715,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Republic Investment Management Inc. bought a new stake in Viewray in the 3rd quarter valued at $562,000. BlackRock Inc. boosted its stake in Viewray by 51.9% in the 3rd quarter. BlackRock Inc. now owns 4,501,045 shares of the company’s stock valued at $42,130,000 after purchasing an additional 1,538,108 shares during the period. Fosun International Ltd boosted its stake in Viewray by 19.6% in the 3rd quarter. Fosun International Ltd now owns 16,471,258 shares of the company’s stock valued at $154,170,000 after purchasing an additional 2,702,702 shares during the period. Oracle Investment Management Inc. bought a new stake in Viewray in the 3rd quarter valued at $2,030,000. Finally, Essex Investment Management Co. LLC boosted its stake in Viewray by 2.9% in the 4th quarter. Essex Investment Management Co. LLC now owns 245,232 shares of the company’s stock valued at $1,489,000 after purchasing an additional 6,897 shares during the period.

Shares of NASDAQ VRAY opened at $8.17 on Tuesday. The company has a quick ratio of 5.56, a current ratio of 6.47 and a debt-to-equity ratio of 0.25. Viewray Inc has a fifty-two week low of $4.86 and a fifty-two week high of $13.21. The firm has a market capitalization of $782.11 million, a price-to-earnings ratio of -8.34 and a beta of 1.30.

Viewray (NASDAQ:VRAY) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. Viewray had a negative return on equity of 71.11% and a negative net margin of 94.36%. The company had revenue of $20.66 million during the quarter, compared to analysts’ expectations of $20.38 million. During the same quarter in the previous year, the firm earned ($0.38) EPS. Viewray’s revenue was up 3.7% on a year-over-year basis. As a group, equities research analysts forecast that Viewray Inc will post -0.73 EPS for the current fiscal year.

Several brokerages have weighed in on VRAY. BidaskClub cut Viewray from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Investment Research raised Viewray from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a report on Saturday, February 9th. ValuEngine cut Viewray from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. B. Riley reaffirmed a “buy” rating and issued a $12.00 price objective (down from $13.75) on shares of Viewray in a report on Monday, March 11th. Finally, Northland Securities reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Viewray in a report on Thursday, December 6th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $12.63.

WARNING: This piece was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://weekherald.com/2019/03/19/perceptive-advisors-llc-purchases-205650-shares-of-viewray-inc-vray.html.

Viewray Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Featured Article: 12b-1 Fees

Want to see what other hedge funds are holding VRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viewray Inc (NASDAQ:VRAY).

Institutional Ownership by Quarter for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.